Welcome to our dedicated page for Mineralys Therapeutics news (Ticker: MLYS), a resource for investors and traders seeking the latest updates and insights on Mineralys Therapeutics stock.
Mineralys Therapeutics, Inc. (Nasdaq: MLYS) is a clinical-stage biopharmaceutical company based in Radnor, Pennsylvania, dedicated to developing innovative medicines for managing hypertension, chronic kidney disease (CKD), and other conditions driven by abnormally elevated aldosterone levels. The company's flagship product, lorundrostat, is an orally administered, highly selective aldosterone synthase inhibitor. This medication is designed to treat patients with uncontrolled hypertension—defined as those unable to achieve blood pressure below 130/80 mmHg even with two or more antihypertensive medications—and resistant hypertension, affecting those who cannot reach the target BP despite taking three or more medications, including a diuretic.
Mineralys Therapeutics aims to revolutionize hypertension management by moving away from the traditional trial-and-error approach and introducing a more personalized treatment strategy. The company’s recent accomplishments underscore this commitment: the publication of their proof-of-concept study, Target-HTN, in the Journal of the American Medical Association, and the initiation of the Phase 3 Launch-HTN and Phase 2 Explore-CKD trials.
The company recently revealed robust financial results for the third quarter of 2023, reporting cash, cash equivalents, and investments totaling $265.9 million as of September 30, 2023, ensuring sufficient funding for planned clinical studies and operations through mid-2025. Mineralys also saw significant increases in both R&D and G&A expenses, attributed to the ramp-up in clinical activities and the transition to operating as a public company.
Mineralys’ lorundrostat has shown promising results in early trials, demonstrating a substantial reduction in plasma aldosterone concentration and clinically meaningful reductions in blood pressure among participants. The company is actively enrolling subjects in pivotal trials and expects to commence the Launch-HTN trial by the end of 2023, targeting real-world applications and responder profiling through biomarker-driven approaches.
Moreover, Mineralys is also focused on chronic kidney disease, which affects over 10% of the global population. Lorundrostat’s potential to treat CKD by targeting aldosterone—an underlying driver in cardiorenal conditions—positions Mineralys at the forefront of tackling complex, interrelated health issues.
For more information, visit their official website at https://mineralystx.com and follow Mineralys on LinkedIn and Twitter.
Mineralys Therapeutics (NASDAQ: MLYS), a clinical-stage biopharmaceutical company, will participate in the Goldman Sachs 45th Annual Global Healthcare Conference in Miami, FL from June 10-13, 2024. The company's management will engage in a fireside chat on June 11, 2024, at 4:00 pm EDT. The discussion will be webcast live and accessible through the Investor Relations section on the Mineralys website, with a replay available for 90 days.
Mineralys Therapeutics, a clinical-stage biopharmaceutical company, reported its first quarter 2024 financial results and provided a corporate update. The company is focused on developing medicines targeting hypertension, chronic kidney disease, and other diseases related to dysregulated aldosterone. Their ongoing clinical trials for lorundrostat are expected to deliver topline data in Q4 2024 and 2H 2025. Mineralys also highlighted its strengthened balance sheet after completing a private placement financing in Q1 2024, providing them with sufficient funds until 2026.
Mineralys Therapeutics, a clinical-stage biopharmaceutical company, will participate in a fireside chat at the Bank of America Securities Health Care Conference. The company focuses on developing medicines for hypertension, chronic kidney disease, and diseases driven by dysregulated aldosterone. The event will take place in Las Vegas on May 14-16, 2024. Investors can access a live webcast and replay of the chat on the company's website.
Mineralys Therapeutics, Inc. (NASDAQ: MLYS) will announce its first quarter 2024 financial results on May 9, 2024. The company focuses on developing medicines for hypertension, chronic kidney disease, and other diseases related to dysregulated aldosterone. The conference call will be hosted at 8:30 a.m. ET, offering dial-in and webcast options for participants.
FAQ
What is the current stock price of Mineralys Therapeutics (MLYS)?
What is the market cap of Mineralys Therapeutics (MLYS)?
What does Mineralys Therapeutics specialize in?
What is lorundrostat?
What recent milestones has Mineralys achieved?
How is Mineralys changing hypertension management?
What are the financial highlights for Mineralys in Q3 2023?
Where is Mineralys Therapeutics headquartered?
How can I follow Mineralys for updates?
What is the significance of aldosterone in hypertension and CKD?
What is the Target-HTN trial?
What is Mineralys' latest product development news?
